Table 1.
The demographics and clinical characteristics of all the TN patients and the subdivision of type 1 and type 2 TN patients. Legend: TN, trigeminal neuralgia; CBZ, carbamazepine; OXC, oxcarbazepine; V1, ophthalmic branch; V2, maxillary branch; V3, mandibular branch; BoNT/A, botulinum toxin type A. A t-test or a Mann–Whitney test was used, as appropriate, to compare continuous variables between type 1 and type 2 TN; a chi-square test was used for qualitative variables.
| Variable | TN | Type 1 TN (Mean ± SD or N°, /%) |
Type 2 TN (Mean ± SD or N°, /%) |
p-Value |
|---|---|---|---|---|
| Number of patients | 40 | 18 | 22 | |
| Age | 63.4 ± 18.4 | 59.9 ± 20.1 | 66.2 ± 16.9 | 0.282 |
| Female sex | 27/40 (67.5%) | 13/18 (72.2%) | 14/22 (63.6%) | 0.564 |
| TN duration (years) | 5.8 ± 4.6 | 4.2 ± 3.9 | 7.0 ± 4.8 | 0.027 |
| Previous oral prophylaxis | 1.3 ± 1.2 | 0.9 ± 1.0 | 1.6 ± 1.1 | 0.051 |
| TN characteristics | ||||
| Left side involved | 19/40 (47.5%) | 9/18 (50.0%) | 10/22 (45.5%) | 0.775 |
| Idiopathic TN | 22/40 (55.0%) | 11/18 (61.1%) | 11/22 (50.0%) | 0.482 |
| Classical TN | 18/40 (45.0%) | 7/18 (38.9%) | 11/22 (50.0%) | 0.537 |
| Only V1 involved | 4/40 (10.0%) | 0/18 (0%) | 4/22 (18.2%) | 0.114 |
| Only V2 involved | 10/40 (25.0%) | 6/18 (33.3%) | 4/22 (18.2%) | 0.300 |
| Only V3 involved | 8/40 (20.0%) | 3/18 (16.7%) | 5/22 (22.7%) | 0.709 |
| V1 + V2 involved | 6/40 (15.0%) | 4/18 (22.2%) | 2/22 (9.1%) | 0.381 |
| V2 + V3 involved | 12/40 (30.0%) | 5/18 (27.8%) | 7/22 (31.8%) | 0.781 |
| BoNT/A dose | 29.5 ± 11.1 | 29.7 ± 11.4 | 29.3 ± 11.0 | 0.967 |